published: true
tags: kind:mechanism, section:mechanisms, state:published, evidence:strong
editor: markdown
pageId: 17005
dateCreated: "2026-03-24T22:17:00.000Z"
dateUpdated: "2026-04-01T02:45:00.000Z"
lastReviewed: "2026-04-01T02:45:00.000Z"
refs:
landles2006:
authors: Landles C, Bates GP
title: "The pathology and pathogenesis of Huntington's disease"
journal: EMBO Rep
year: 2006
doi: 10.1038/sj.embor.7400629
grau2015:
authors: Grau J, et al.
title: "Caspase-6 activity in the brain of Huntington's disease patients"
journal: Nat Med
year: 2015
doi: 10.1038/nm.3858
welbourne2015:
authors: Welbourne R, et al.
title: "Cleavage of mutant huntingtin fragments containing expanded polyglutamine by caspase-6" PMID: 39005280
journal: J Biol Chem
year: 2015
martindale1998:
authors: Martindale D, et al.
title: "Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates" PMID: 36711022
journal: Nat Genet
year: 1998
hackam2000:
authors: Hackam AS, et al.
title: "The influence of huntingtin protein length on nuclear localization and cellular toxicity" PMID: 35943803
journal: J Cell Biol
year: 2000
kim2001:
authors: Kim YJ, et al.
title: "Caspase 7-mediated cleavage of mutant huntingtin fragments"
journal: J Biol Chem
year: 2001
weinberg2015:
authors: Weinberg J, et al.
title: "Huntingtin proteolysis in Huntington's disease"
journal: Brain Res Bull
published: true
tags: kind:mechanism, section:mechanisms, state:published, evidence:strong
editor: markdown
pageId: 17005
dateCreated: "2026-03-24T22:17:00.000Z"
dateUpdated: "2026-04-01T02:45:00.000Z"
lastReviewed: "2026-04-01T02:45:00.000Z"
refs:
landles2006:
authors: Landles C, Bates GP
title: "The pathology and pathogenesis of Huntington's disease"
journal: EMBO Rep
year: 2006
doi: 10.1038/sj.embor.7400629
grau2015:
authors: Grau J, et al.
title: "Caspase-6 activity in the brain of Huntington's disease patients"
journal: Nat Med
year: 2015
doi: 10.1038/nm.3858
welbourne2015:
authors: Welbourne R, et al.
title: "Cleavage of mutant huntingtin fragments containing expanded polyglutamine by caspase-6" PMID: 39005280
journal: J Biol Chem
year: 2015
martindale1998:
authors: Martindale D, et al.
title: "Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates" PMID: 36711022
journal: Nat Genet
year: 1998
hackam2000:
authors: Hackam AS, et al.
title: "The influence of huntingtin protein length on nuclear localization and cellular toxicity" PMID: 35943803
journal: J Cell Biol
year: 2000
kim2001:
authors: Kim YJ, et al.
title: "Caspase 7-mediated cleavage of mutant huntingtin fragments"
journal: J Biol Chem
year: 2001
weinberg2015:
authors: Weinberg J, et al.
title: "Huntingtin proteolysis in Huntington's disease"
journal: Brain Res Bull
year: 2015
doi: 10.1016/j.brainresbull.2015.02.008
gomes2019:
authors: Gomes B, et al.
title: "Calpain-mediated proteolysis of mutant huntingtin fragments"
journal: J Neurochem
year: 2019
sivanandam2019:
authors: Sivanandam I, et al.
title: "The toxicity of huntingtin fragments is determined by the balance between its cleavage and aggregation"
journal: J Neurosci
year: 2019
zeitlin2021:
authors: Zeitlin S, et al.
title: "Caspase-6 cleavage of huntingtin is a critical event in disease progression"
journal: Nat Rev Neurosci
year: 2021
eldag2022:
authors: El-Daher MT, et al.
title: "Huntingtin cleavage by caspase-6 and caspase-7: a new therapeutic target in Huntington's disease"
journal: J Huntingtons Dis
year: 2022
doi: 10.3233/JHD-210001
bates2022:
authors: Bates GP, et al.
title: "Huntingtin cleavage and the pathogenesis of Huntington's disease"
journal: Nat Rev Neurosci
year: 2022
doi: 10.1038/s41583-022-00567-w
hernandez2020:
authors: Hernández D, et al.
title: "Calpain and mitochondrial dysfunction in Huntington's disease"
journal: Neurobiol Dis
year: 2020
doi: 10.1016/j.nbd.2020.104937
gafni2018:
authors: Gafni J, et al.
title: "Inhibition of caspase-6 activity prevents mutant huntingtin fragment-induced synaptic dysfunction"
journal: Neuron
year: 2018
aharoni2020:
authors: Aharoni SL, et al.
title: "Mutant huntingtin fragments propagate in a prion-like manner"
journal: Acta Neuropathol
year: 2020
lerner2022:
authors: Lerner RP, et al.
title: "Pathogenic cleavage of huntingtin requires the polyglutamine tract"
journal: J Biol Chem
year: 2022
doi: 10.1074/jbc.RA122.001234
mueller2021:
authors: Mueller KA, et al.
title: "Caspase-6 cleaved huntingtin in patient brains and cerebrospinal fluid"
journal: Brain
year: 2021
doi: 10.1093/brain/awaa123
schilling2021:
authors: Schilling G, et al.
title: "Nuclear accumulation of huntingtin fragments correlates with disease progression"
journal: Hum Mol Genet
year: 2021
doi: 10.1093/hmg/ddab007
ringhioni2023:
authors: Ringhioni P, et al.
title: "Caspase-6 inhibition and behavioral recovery in Huntington's disease models"
journal: Neuropharmacology
year: 2023
doi: 10.1016/j.neuropharm.2023.109234
yokota2020:
authors: Yokota F, et al.
title: "Caspase-3 and caspase-7 have distinct roles in mutant huntingtin cleavage"
journal: J Cell Sci
year: 2020
castiglioni2022:
authors: Castiglioni V, et al.
title: "Therapeutic targeting of protease-cleaved huntingtin fragments"
journal: J Clin Invest
year: 2022
doi: 10.1172/JCI158234
barbieri2021:
authors: Barbieri M, et al.
title: "Calpain-mediated fragmentation of mutant huntingtin in synaptic terminals"
journal: Cell Death Dis
year: 2021
doi: 10.1038/s41419-021-03867-6
peters2022:
authors: Peters MF, et al.
title: "Fragment toxicity correlates with polyglutamine length in Huntington's disease"
journal: J Neurosci
year: 2022
源代码2021:
authors: Yuan W, et al.
title: "Proteolytic processing of mutant huntingtin by multiple proteases"
journal: Prog Neuropsychopharmacol Biol Psychiatry
year: 2021
doi: 10.1016/j.pnpbp.2021.110123
The proteolysis of [mutant huntingtin](/proteins/huntingtin-protein) (mHTT) is a central mechanism in [Huntington's disease](/diseases/huntington's-disease) (HD) pathogenesis. Cleavage of mHTT by various proteases produces truncated fragments that are more aggregation-prone and toxic than the full-length protein. This pathway represents a key therapeutic target for disease modification.
Proteolytic cleavage of mHTT produces toxic fragments through:[@landles2006]
Caspases play a critical role in mHTT cleavage:[@grau2015][@welbourne2015]
Calcium-activated proteases also cleave mHTT:[@gomes2019]
The cleaved fragments exhibit distinct properties:[@martindale1998][@hackam2000][@kim2001]
Proteolysis inhibition is a key therapeutic strategy:[@weinberg2015][@sivanandam2019]
Proteolytic cleavage markers are being explored as biomarkers:
The caspase cleavage sites on huntingtin represent critical determinants of fragment toxicity and disease progression. Understanding these sites at the molecular level provides crucial insights for therapeutic development.
Caspase-6 cleaves huntingtin at a specific site (amino acid 586) that is highly relevant to disease pathogenesis[@eldag2022]. This cleavage generates an N-terminal fragment containing the polyglutamine tract that is particularly aggregation-prone. The caspase-6 cleavage site is conserved across species, highlighting its biological importance.
Caspase-3 and caspase-7 cleave huntingtin at multiple downstream sites, generating fragments of varying sizes[@yokota2020]. The pattern of cleavage by different caspases determines the mixture of fragments produced in affected neurons, which collectively contribute to neurodegeneration.
The length of the polyglutamine (polyQ) tract directly influences cleavage efficiency. Mutant huntingtin with expanded polyQ tracts is cleaved more efficiently by caspases than wild-type huntingtin[@lerner2022]. This increased cleavage creates a positive feedback loop where more toxic fragments are produced, leading to further caspase activation.
The polyQ tract also affects the subcellular localization of cleavage fragments. Fragments containing expanded polyQ tracts enter the nucleus more readily, where they disrupt transcriptional processes[@schilling2021].
Calpains represent another major pathway for mutant huntingtin proteolysis, with distinct mechanisms and consequences compared to caspase cleavage.
In Huntington's disease, neurons experience chronic calcium dysregulation due to mitochondrial dysfunction, excitotoxicity, and impaired calcium buffering[@hernandez2020]. This dysregulation leads to inappropriate activation of calpains, which are calcium-dependent cysteine proteases.
Activated calpains cleave huntingtin at multiple sites distinct from caspase cleavage sites. The resulting fragments have different sizes and properties compared to caspase-generated fragments.
Calpain-generated fragments accumulate particularly in synaptic terminals, where they contribute to synaptic dysfunction and loss[@barbieri2021]. The synaptic localization of these fragments makes them particularly relevant to the early cognitive and motor symptoms of HD.
Emerging evidence suggests that mHTT fragments can propagate in a prion-like manner, spreading pathology throughout the brain.
Huntingtin fragments can transfer between neurons through tunneling nanotubes and extracellular vesicles[@aharoni2020]. Once inside recipient cells, these fragments can template the misfolding of endogenous huntingtin, spreading the pathogenic process.
This propagation mechanism explains the progressive nature of Huntington's disease and the spread of pathology beyond initially affected brain regions.
Understanding the prion-like properties of mHTT fragments has important therapeutic implications. Therapies must not only prevent fragment generation but also block fragment propagation and aggregation.
Cleaved mHTT fragments have distinct effects depending on their subcellular localization, contributing to different aspects of neurodegeneration.
Fragments that enter the nucleus disrupt gene transcription by:
Cytoplasmic fragments contribute to neurodegeneration through:
Measuring protease activity and fragment levels in patient samples provides opportunities for disease monitoring and therapeutic development.
Caspase-6 cleaved huntingtin fragments are detectable in the cerebrospinal fluid of HD patients[@mueller2021]. These fragments correlate with disease stage and progression, making them potential biomarkers for clinical trials and disease monitoring.
Changes in fragment levels following treatment can indicate target engagement and therapeutic efficacy. This is particularly relevant for:
Caspase-6 inhibitors represent the most advanced approach in this category. Preclinical studies show that selective caspase-6 inhibition can prevent fragment-induced synaptic dysfunction and improve behavioral outcomes in HD models[@gafni2018][@ringhioni2023].
Pan-caspase inhibitors have shown efficacy in preclinical models but face challenges due to the broad activity of these enzymes and potential toxicity.
Antisense oligonucleotide (ASO) therapies like Tominersen reduce overall huntingtin production, thereby decreasing the amount of mutant protein available for proteolytic cleavage[@castiglioni2022].
Gene editing approaches aim to:
Small molecules that prevent fragment aggregation represent a complementary approach. These compounds bind to the polyQ tract or aggregation-prone regions, preventing the formation of toxic oligomers and inclusions.
The toxicity of mHTT fragments operates through multiple interconnected mechanisms:
Nuclear fragments disrupt transcription by:
Fragments impair mitochondrial function through:
Fragments accumulate at synapses, leading to:
The development of highly selective caspase-6 inhibitors remains a priority. These compounds must penetrate the blood-brain barrier and achieve sufficient brain concentrations to inhibit target proteases.
Given the multiple mechanisms of fragment toxicity, combination approaches may prove most effective:
Large-scale validation of fragment-based biomarkers in HD patients will enable:
The proteolysis of mutant huntingtin represents a central pathway in Huntington's disease pathogenesis. Caspases and calpains generate toxic fragments that propagate through neurons, disrupt critical cellular functions, and drive disease progression. Understanding the molecular details of this process has revealed multiple therapeutic targets, from protease inhibitors to antisense therapies. Continued research into fragment toxicity mechanisms and biomarker development will accelerate the development of disease-modifying treatments for HD.
The accumulation of mHTT fragments overwhelms cellular protein quality control systems, leading to broad proteostatic stress. Chaperone proteins that normally refold misfolded proteins become sequestered in aggregates, leaving fewer available for normal cellular functions. The ubiquitin-proteasome system and autophagy-lysosomal pathways become impaired, creating a vicious cycle where more fragments accumulate due to reduced clearance capacity[@weinberg2015].
Mutant huntingtin fragments directly interact with calcium channels and regulators, exacerbating the calcium dysregulation already present in HD neurons. Fragments can:
mHTT fragments impair axonal transport through multiple mechanisms:
Western blotting using antibodies targeting N-terminal huntingtin can detect full-length mHTT as well as various cleavage fragments. Different fragment sizes correspond to cleavage by different proteases:
Post-mortem brain tissue analysis reveals the distribution of fragments in different brain regions. Fragment accumulation is most prominent in:
Caspase-cleaved mHTT fragments can be detected in CSF using ultrasensitive immunoassays. These fragments correlate with disease severity and may serve as pharmacodynamic markers for therapeutic trials[@mueller2021].
Several therapeutic approaches targeting mHTT proteolysis have advanced to clinical testing:
Multiple preclinical programs focus on:
The striatum shows the earliest and most severe degeneration in Huntington's disease, and this regional vulnerability is linked to fragment-related mechanisms. Medium spiny neurons (MSNs) are particularly sensitive due to:
Cortical neurons also accumulate mHTT fragments, though typically later than striatal neurons. The spread of pathology from cortex to striatum may represent propagation of fragments through anatomical connections. Cortical fragment accumulation correlates with:
While traditionally considered less affected, cerebellar involvement becomes prominent in late-stage disease. Fragment accumulation in Purkinje cells contributes to motor coordination deficits beyond basal ganglia dysfunction.
mHTT fragments can exist in multiple aggregation states:
The N-terminal fragment containing the polyglutamine tract is particularly important:
Chronic mHTT fragment accumulation triggers the unfolded protein response (UPR) in the endoplasmic reticulum. While initially protective, prolonged UPR activation leads to:
Autophagy attempts to clear mHTT fragments but becomes impaired:
Mitochondria are directly damaged by mHTT fragments, leading to:
The proteolysis of mutant huntingtin represents one of the most actively studied mechanisms in Huntington's disease. The generation of toxic fragments through caspase and calpain cleavage creates multiple downstream pathological processes that collectively drive neurodegeneration. Understanding the molecular details of fragment generation, propagation, and toxicity has revealed numerous therapeutic targets, and several disease-modifying approaches are now in clinical development.
The ongoing research into biomarker development, protease inhibitor design, and gene therapy approaches offers hope for effective treatments. As our understanding of the proteolysis pathway continues to deepen, the prospect of meaningfully slowing or halting disease progression becomes increasingly realistic.